CGT Global Welcomes Dr. Jerome Ritz to Its Board of Advisors, Enriching Knowledge of Cellular Therapies and Hematology

Audio By Carbonatix

FOLSOM, Calif.--(BUSINESS WIRE)--Aug 14, 2025--

CGT Global, a biotechnology leader accelerating access to life-changing cell and gene therapies, today announced the appointment of Jerome Ritz, MD, to its Board of Advisors. Dr. Ritz brings a distinguished career in hematology, oncology, cell manufacturing, and the advancement of cell and gene therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814468290/en/

CGT Global Welcomes Dr. Jerome Ritz to Its Board of Advisors

Dr. Ritz received his MD from Chicago Medical School in 1972, followed by a residency in internal medicine at the University of Wisconsin Hospital and Clinics, Madison. He completed a clinical fellowship in hematology and oncology at Beth Israel Hospital and a research fellowship at Dana-Farber Cancer Institute (DFCI), where he joined the staff in 1980. He has been Professor of Medicine at DFCI, Brigham and Women’s Hospital and Harvard Medical School since 1996. His profound expertise in cellular therapies is underscored by his founding of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) in 1996. Under his leadership, the CMCF has become a premier academic GMP cell manufacturing facility that has supported a large number of early phase cell and gene therapy clinical trials conducted at many clinical sites in Boston and throughout the United States.

"We are incredibly honored to have Dr. Jerome Ritz join our Board of Advisors," said Cate Spears, CGT Global CEO Founder. "Dr. Ritz's extensive background in cell and gene therapies and his deep understanding of hematology and oncology are paramount to our mission. His long-standing leadership directly aligns with our commitment to create scalability for cell and gene therapies. His insights will be invaluable as we continue to push therapeutic boundaries and expand patient access."

Dr. Ritz's career has been marked by significant contributions to the understanding and application of cellular therapies, particularly within hematologic malignancies. His directorship of a key cell manufacturing facility highlights his practical and strategic expertise in handling and processing cells for therapeutic applications.

"I am delighted to join the Board of Advisors at CGT Global," said Dr. Ritz. "The company's approach to accelerating the development of cell and gene therapies and especially their vision for expanding patient access to these new therapies is needed to establish sustainable economic scalability to the industry. I look forward to contributing my experience in cell manufacturing and clinical hematology/oncology to help CGT Global further its vital work in bringing these innovative, life-saving treatments to patients."

About CGT Global

CGT Global is a biotechnology leader accelerating access to life-changing cell and gene therapies. Through its national footprint of clinical sites and laboratories, CGT Global delivers high-quality biospecimens, GMP-compliant manufacturing, and end-to-end clinical trial support and patient care to drive therapeutic breakthroughs and expand patient access. Headquartered in Folsom, CA, CGT Global partners with top pharmaceutical companies, CROs, and hospitals. Learn more at www.cgt.global.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250814468290/en/

CONTACT: Sharon Jacobson Franz

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH GENETICS GENERAL HEALTH RESEARCH SCIENCE BIOTECHNOLOGY

SOURCE: CGT Global

Copyright Business Wire 2025.

PUB: 08/14/2025 09:00 AM/DISC: 08/14/2025 09:00 AM

http://www.businesswire.com/news/home/20250814468290/en